A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity
Active Not Recruiting
The main purpose of this study is to determine if combining tirzepatide with mibavademab will result in more weight loss in adult participants than tirzepatide alone. The study will last about 74 weeks and may include up to 19 visits.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: Tandem Clinical Research, Marrero, Louisiana +1 locations
Conditions: Obesity
Anti-obesity Pharmacotherapy and Inflammation
Active Not Recruiting
This study evaluates the relationship between weight loss, circulating inflammatory markers and lipids from 24 patients before and after 6 months of pharmacotherapy as a standard of care for anti-obesity treatment
Gender:
ALL
Ages:
Between 35 years and 60 years
Trial Updated:
01/08/2025
Locations: LSU Clinical & Translational Research Center (CTRC - - LSUHSC-NO, New Orleans, Louisiana +1 locations
Conditions: Obesity
A Study of Tirzepatide in Participants With Impaired Liver Function
Completed
The purpose of this study is to assess how fast tirzepatide gets into the blood stream and how long it takes the body to remove it in participants with impaired liver function compared to healthy participants. The study will last about two months and will include five visits to the study center.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
06/09/2022
Locations: New Orleans Center for Clinical Research, New Orleans, Louisiana
Conditions: Hepatic Insufficiency